Clinical leadership Actafarma emphasizes strong R&D investment and clinical safety testing, including a nutraceutical with clinical safety studies in humans. This positions the company as a scientifically credible partner for health-focused product development and regulatory-compliant collaborations.

Global expansion With a pipeline delivering multiple releases annually (2013-2018) and a strategy to expand across Europe, North, Central, and South America, Actafarma presents opportunities for distribution partnerships, co-development deals, and market-entry collaborations in multiple regions.

Diverse portfolio A 44-reference portfolio spanning longevity, joints, metabolism, weight control, and cosmetics suggests cross-sell potential to existing clients and potential co-branding opportunities for complementary product lines.

Academic ties Collaborations with CSIC, universities, and research institutes indicate a receptiveness to joint research, clinical trials, and grant-supported initiatives that SDs can leverage for co-funded programs or sponsored research partnerships.

Mid-market fit With 51-200 employees and revenue between $1M-$10M, Actafarma sits in a mid-market segment where targeted distributors, contract manufacturing, and regional sales channels could optimize reach, while offering scalable procurement synergies for larger buyers.